Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here


Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

 
Bookmark and Share
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
Diabetes News
Clinical trials testing therapies for diabetes

Latest Top (15) News


A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Afrezza plus One Drop | Premium;   Other: One Drop | Premium
Sponsors:   Informed Data Systems, Inc.;   Mannkind Corporation
Recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Conditions:   Acute Cellular Graft Rejection;   Liver Transplant Rejection
Interventions:   Drug: Budesonide;   Drug: Tacrolimus(FK506);   Drug: Mycophenolate Mofetil;   Drug: Prednisone
Sponsor:   Montefiore Medical Center
Not yet recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes
Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: FAST;   Other: Standard of care
Sponsors:   Joyce Lee;   National University, Singapore;   Tan Tock Seng Hospital;   National Healthcare Group, Singapore
Recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Duality of Lipids: the Athlete's Paradox
Conditions:   Insulin Resistance, Diabetes;   Lipid Metabolism Disorders
Intervention:   Procedure: Acute bout of endurance exercise
Sponsor:   German Diabetes Center
Recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Not yet recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction
Conditions:   STEMI - ST Elevation Myocardial Infarction;   Glucagon-like Peptide-1;   Bleeding;   Complications
Intervention:  
Sponsor:   Chinese PLA General Hospital
Completed

Thu, 19 Oct 2017 12:00:00 EDT


Risk Factors for Hearing Loss as a Result of Exposure to Noise During Military Training in the IDF
Condition:   Hearing Loss, Noise-Induced
Intervention:   Other: Guidance on auditory protection
Sponsor:   Medical Corps, Israel Defense Force
Recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.
Conditions:   Diabete Mellitus;   Obstructive Sleep Apnea
Intervention:   Diagnostic Test: polysomnography
Sponsor:   Centre Hospitalier Universitaire Saint Pierre
Recruiting

Thu, 19 Oct 2017 12:00:00 EDT


Berlin-Brandenburg Pregnancy Cohort
Conditions:   Preeclampsia;   Pregnancy Complications;   Diabetes Mellitus in Pregnancy
Intervention:  
Sponsor:   Charite University, Berlin, Germany
Recruiting

Wed, 18 Oct 2017 12:00:00 EDT


Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
Condition:   Diabetic Foot Ulcer
Intervention:   Device: Restrata TM Wound Matrix
Sponsor:   Acera Surgical, Inc.
Recruiting

Wed, 18 Oct 2017 12:00:00 EDT


Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
Condition:   Diabetes
Interventions:   Drug: Cabergoline;   Drug: Gliclazide
Sponsor:   Tanta University
Recruiting

Wed, 18 Oct 2017 12:00:00 EDT


Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Guazuma Ulmifolia plus Tecoma Stans;   Drug: Calcinaned magnesia
Sponsor:   Centro Universitario de Ciencias de la Salud, Mexico
Completed

Wed, 18 Oct 2017 12:00:00 EDT


Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
Conditions:   Type2 Diabetes Mellitus;   Stable Coronary Artery Disease
Interventions:   Drug: Dapagliflozin 10Mg Tab;   Other: Placebo
Sponsor:   Andrea Giaccari
Recruiting

Wed, 18 Oct 2017 12:00:00 EDT


Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: AZD4017;   Drug: Placebo
Sponsor:   University of Leeds
Not yet recruiting

Wed, 18 Oct 2017 12:00:00 EDT


Preventing Diabetes With Digital Health and Coaching
Condition:   PreDiabetes
Interventions:   Behavioral: Online diabetes prevention program;   Behavioral: Standard Care
Sponsors:   Omada Health, Inc.;   University of Nebraska;   Wake Forest University Health Sciences
Not yet recruiting

Wed, 18 Oct 2017 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News


FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).

Wed, 18 Oct 2017 17:37:00 -0400


FDA clears new robotically-assisted surgical device for adult patients
Today, the U.S. Food and Drug Administration cleared the Senhance System, a new robotically-assisted surgical device (RASD) that can help facilitate minimally invasive surgery.

Fri, 13 Oct 2017 16:14:00 -0400


California dietary supplement maker, Custompax prohibited from manufacturing
A California dietary supplement manufacturer recently was ordered by a federal court to stop selling its products until the company comes into compliance with the U.S. Food and Drug Administration’s dietary supplement manufacturing regulations and other requirements listed in a consent decree.

Fri, 13 Oct 2017 12:14:00 -0400


Statement by FDA Commissioner Scott Gottlieb, M.D. on Baxter manufacturing recovery in Puerto Rico
Statement by FDA Commissioner Scott Gottlieb, M.D. on Baxter manufacturing recovery in Puerto Rico

Fri, 13 Oct 2017 08:31:00 -0400


FDA clears first 7T magnetic resonance imaging device
Today, the U.S. Food and Drug Administration cleared the first seven tesla (7T) magnetic resonance imaging (MRI) device, more than doubling the static magnetic field strength available for use in the United States. The Magentom Terra is the first 7T MRI system cleared for clinical use in the United States.

Thu, 12 Oct 2017 10:45:00 -0400


Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work
The Food and Drug Administration is hosting a pioneering event today: the first meeting of the Patient Engagement Advisory Committee or PEAC. It’s a significant step forward in the FDA’s efforts to broaden its engagement with patients – and to deepen the involvement of patients in our regulatory activities.

Wed, 11 Oct 2017 11:52:00 -0400


FDA approves implantable device to treat moderate to severe central sleep apnea
The U.S. Food and Drug Administration today approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea. The Remedē System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.

Fri, 06 Oct 2017 16:55:00 -0400


Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA’s continued assistance following the natural disaster in Puerto Rico
FDA continues extensive efforts to provide direct assistance to the residents of Puerto Rico following Hurricanes Irma and Maria, and is taking new steps to mitigate the impact of these twin disasters on the island’s vibrant medical product manufacturing sector. Our top priority is the people of Puerto Rico.

Fri, 06 Oct 2017 15:23:00 -0400


FDA awards 15 grants for clinical trials to stimulate product development for rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country.

Fri, 06 Oct 2017 10:33:00 -0400


FDA awards six grants for natural history studies in rare diseases
The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time. One potential application of these studies is the opportunity to eventually use natural history models to augment the need for placebo arms in studies of drugs that target very rare disease, where trial recruitment can be challenging.

Fri, 06 Oct 2017 10:32:00 -0400
Diabetes news from the American Diabetes Association

Latest Top (5) News